At Blueleaf, the combined company formed by NHG and Clinicare Supplies, we empower the success of care homes around the world through the passion of our people and smart solutions. Blueleaf provides one of the most comprehensive ranges of products and services - from consumables and equipment, to furniture and interior design.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

AMBERSTONE BIOSCIENCES SECURES $12 MILLION SERIES A FINANCING TO ADVANCE IMMUNO-ONCOLOGY PIPELINE OF TUMOR MICROENVIRONMENT ACTIVATED THERAPEUTICS

Amberstone Biosciences, Inc. | January 04, 2022

news image

Amberstone Biosciences an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, today announced the completion of a $12 million Series A financing round. The funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital, Lifespan Investments and existing shareholders. Amberstone will use the proceeds from the financing to advance its highly differentiated tumor microenviron...

Read More

Industrial Impact

HOW MIGHT BIOMOLECULAR CONDENSATES REVOLUTIONIZE DRUG DISCOVERY? A PERSPECTIVE FROM DEWPOINT THERAPEUTICS

Dewpoint Therapeutics | August 18, 2022

news image

A new perspective published in Nature Reviews Drug Discovery examines the potential of biomolecular condensates to transform drug discovery. Condensates are membrane-less organelles that form dynamically throughout the cell via a process called phase separation. Over the last decade scientists have recognized the role of biomolecular condensates in cellular organization and disease, marking one of the most revolutionary areas of biology. In "Modulating biomolecular condensate...

Read More

SMART MONEY IS RACING INTO THE BIOTECH BOOM

FN Media Group | May 08, 2020

news image

The biotech boom is back. After its big breakthrough a few years ago, the biotech industry fell silent. Now, it is in the spotlight once again as smart money races in to back some once-in-a-generation breakthroughs. Mentioned in today's commentary includes: CRISPR Therapeutics AG (NASDAQ: CRSP), Sangamo Therapeutics, Inc. (NASDAQ: SGMO), Microsoft Corporation (NASDAQ: MSFT), International Business Machines Corporation (NYSE: IBM), Apple Inc. (NASDAQ: AAPL).From exciti...

Read More

Industrial Impact

IMAGINAB EXECUTES NEW LICENSE AND SUPPLY AGREEMENT FOR CD8 IMMUNOPET TECHNOLOGY WITH TRISALUS LIFE SCIENCES

ImaginAb | November 23, 2022

news image

ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam imaging agent and radiopharmaceutical therapy products, is pleased to announce the signing of a new non-exclusive License and Supply Agreement with TriSalus Life Sciences, Inc. an oncology therapeutics company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors. Under the terms of the agreement, ImaginAb wil...

Read More
news image

Industrial Impact

AMBERSTONE BIOSCIENCES SECURES $12 MILLION SERIES A FINANCING TO ADVANCE IMMUNO-ONCOLOGY PIPELINE OF TUMOR MICROENVIRONMENT ACTIVATED THERAPEUTICS

Amberstone Biosciences, Inc. | January 04, 2022

Amberstone Biosciences an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, today announced the completion of a $12 million Series A financing round. The funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital, Lifespan Investments and existing shareholders. Amberstone will use the proceeds from the financing to advance its highly differentiated tumor microenviron...

Read More
news image

Industrial Impact

HOW MIGHT BIOMOLECULAR CONDENSATES REVOLUTIONIZE DRUG DISCOVERY? A PERSPECTIVE FROM DEWPOINT THERAPEUTICS

Dewpoint Therapeutics | August 18, 2022

A new perspective published in Nature Reviews Drug Discovery examines the potential of biomolecular condensates to transform drug discovery. Condensates are membrane-less organelles that form dynamically throughout the cell via a process called phase separation. Over the last decade scientists have recognized the role of biomolecular condensates in cellular organization and disease, marking one of the most revolutionary areas of biology. In "Modulating biomolecular condensate...

Read More
news image

SMART MONEY IS RACING INTO THE BIOTECH BOOM

FN Media Group | May 08, 2020

The biotech boom is back. After its big breakthrough a few years ago, the biotech industry fell silent. Now, it is in the spotlight once again as smart money races in to back some once-in-a-generation breakthroughs. Mentioned in today's commentary includes: CRISPR Therapeutics AG (NASDAQ: CRSP), Sangamo Therapeutics, Inc. (NASDAQ: SGMO), Microsoft Corporation (NASDAQ: MSFT), International Business Machines Corporation (NYSE: IBM), Apple Inc. (NASDAQ: AAPL).From exciti...

Read More
news image

Industrial Impact

IMAGINAB EXECUTES NEW LICENSE AND SUPPLY AGREEMENT FOR CD8 IMMUNOPET TECHNOLOGY WITH TRISALUS LIFE SCIENCES

ImaginAb | November 23, 2022

ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam imaging agent and radiopharmaceutical therapy products, is pleased to announce the signing of a new non-exclusive License and Supply Agreement with TriSalus Life Sciences, Inc. an oncology therapeutics company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors. Under the terms of the agreement, ImaginAb wil...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us